Facial-facial anastomosis (FFA), i.e., suture of transected facial nerve, was performed in adult Wistar rats. For 1 O-l 12 d postoperation (DPO), half of the animals received standard food (placebo) and half received food pellets containing 1000 ppm nimodipine, a Ca2+ channel blocker. The time course of mimetic reinnervation between these two groups was compared by counting all retrogradely labeled motoneurons after injection of horseradish peroxidase (HRP) into the whiskerpad.
In unoperated animals, injection of HRP labeled 1280 t 113 motoneurons. After FFA, this number dropped to zero, and the first HRP-labeled facial motoneurons reappeared in both placeboand nimodipine-treated animals at 14 DPO. The treatment with nimodipine yielded two beneficial effects.
(1) It accelerated axonal sprouting until 28 DPO. Whereas the number of HRPlabeled cells in the placebo group was 171 ? 9 (mean 2 SD) at 16 DPO, 372 5 43 at 21 DPO, and 636 -C 187 at 28 DPO, the number of sprouted motoneurons in nimodipine-treated rats was twice as high: 386 5 34 at 16 DPO, 620 ? 28 at 21 DPO, and 756 ?I 257 at 28 DPO. (2) Nimodipine reduced the polyneuronal innervation of the target muscles. Whereas the number of HRP-labeled cells in the placebo group increased to 1430 ? 36 at 56 DPO and 1600 2 31 at 112 DPO, the number of labeled motoneurons in nimodipine-treated rats remained almost within the normal range: 1315 5 31 at 56 DPO and 1354 5 33 at 112 DPO.
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The outgrowth of regenerating axons of a transected peripheral motor nerve is a slow process. After an initial delay, which is necessary for the cell bodies to compensate for the retrograde effects of axonal transection, the regenerating axonal sprouts cross the site of injury, reach the distal stump, and grow down the nerve to their peripheral terminations (Thomas, 1988; Fawcett and Keynes, 1990; Liuzzi and Tedeschi, 1991) . The speed of this regeneration varies from 0.6 to 4.2 mm/d (Seddon et al., 1943; Jasper, 1946; Sunderland, 1946; Isch et al., 1968; Braam and Nicolai, 1993) , with a mean value of -1 mm/d in humans (Guth, 1956; Thomas, 1988) . For example, in a case with lesioned facial nerve, this regeneration rate would promote a dysfunction of the facial nerve for several months. This facial palsy causes great morbidity for the sufferer which, in combination with the grotesque disfigurement, often may lead to a psychological incapacitation (Bento and Miniti, 1993; Braam and Nicolai, 1993; Vaughan and Richardson, 1993) .
Obviously, it would be desirable to accelerate the axonal sprouting. However, all pharmacological treatment strategies, including trophic factors, gangliosidcs, and phosphatidylserine, have not been as successful as expected (Gottfries, 1989; Pepeu et al., 1993 that the Ca2+ entry blocker nimodipine accelerates the axonal resprouting after nerve suture. Calcium ions play a crucial role in depolarization, outgrowth, excitability, aging, learning, and cell proliferation-in short, neuronal plasticity (Gispen et al., 1988) . It is well known that peripheral nerve injury disrupts the permeability barrier function of the plasma membrane, allowing an influx of Ca2+ down a steep electrochemical gradient between the outside and the inside of the cell (Borgens, 1988) . The resultant intracellular free Ca2+ overload triggers a wide array of chain reactions, which eventually may lead to cell death (Schanne et al., 1979; Choi, 1988) . Therefore, an agent preventing the excessive influx of Ca'+ (e.g., Ca'-Ichannel blocker) might attenuate cellular damage caused by mechanical neuronal injury and thus improve neuronal recovery (Takimoto and Fujibayashi, 1988) .
We tested the Ca2+ channel blocker nimodipine (1,4,-dihydropyridine,
or Bay E-9736) because this drug has been shown previously (1) to reduce the age-related deterioration of motor performance (Schuurman et al., 1987; Van der Zee et al., 1990; Ingram et al., 1994) , (2) to favor the functional recovery of gait after crush lesion of the rat sciatic nerve (Van der Zee et al., 1987 , 1991 Gispen et al., 1988; Bar et al., 1990) , (3) to attenuate neuronal damage after cerebral ischemia (Mabe et al., 1986; Choi, 1988; Uematsu et al., 1989; Nyakas et al., 1994) , and (4) to provide a variable but significant neuroprotection after traumatic insult to murine cortical neurons and glia (Regan and Choi, 1994) .
MATERIALS AND METHODS
The design of our experiment was simple: after transection and imme- et al., 1982; Yu and Yu, 1983; Hinrichsen and Watson, 1984; Thomander, 1984; Friauf and Herbert, 1985; Klein and Rhoades, 1985; Aldskogius and Thomander, 1986; Semba and Egger, 1986; Angelov et al., 1993 After FFA, 60 rats were kept on Ssnitf food pellets (standard formula rat/mouse), which served as placebo treatment.
Nimodipine-treated animals.
Starting immediately after surgery and ending with the perfusion fixation, 60 rats received special pellets, which were based on Ssniff standard formula for rat/mouse diet and contained 1000 ppm nimodipine supplied by Bayer (Leverkusen, Germany; pellets made by Ssniff). It is well known that most Ca*+ channel blockers are highly potent drugs and that their therapeutic concentrations in plasma and other biological fluids generally are within the range of high picograms to low nanograms per milliliter (Formenti et al., 1993; Muck and Bode, 1994) . In addition, it has been shown previously that clinically convenient oral administration of the drug causes a virtually complete and rapid absorption in the gastrointestinal tract (Raemsch ct al., 1985; Wadworth and McTavish, 1992; Herbette et al., 1994) . Finally, the daily dosage chosen was in accordance with the study of Van der Zee et al. (1991) , which reported acceleration of functional recovery after crush lesion of the rat sciatic nerve. To allow for retrograde transport, HRP was always applied 4X hr before fixation of the animal (e.g., for investigation at 14 DPO, HRP was administered at 12 DPO).
Six rats per group were fixed by perfusion after the same postopcrativc survival times as after placebo treatment. , 1986) . There is no other motor nerve supply to these muscles except from the lateral subdivision of the facial nucleus (Papcz, 1927; Martin et al., 1977; Watson et al., 1982; Hinrichscn and Watson, 1984) . HRP was injected into the whiskerpads of all rats bilaterally, i.e., both on the operated and on the contralateral untreated control side. Because we wanted to compare the numbers of labeled nerve cells in diffcrcnt animals, great care was taken to ensure identical conditions of injection in each animal. Under deep ether narcosis, 2 mg of HRP (Type VI-A: Sigma, St. Louis, MO) dissolved in 0.2 ml of distilled water containing 2% dimethylsulfoxide was injected under the skin of each whiskerpad (on the operated and on the unoperated side), always at the same site, i.c., exactly in the middle between dorsal vibrissal rows A and B (Arvidsson, 1982; Angelov et al., 1993) . Forty-eight hours later, the animals were fixed by perfusion (see below).
Application of HRP

Tissue processing
Fkatiorl.
All animals were anesthetized and pericardially perfused with 0.9% NaCl in distilled water for 30 set, followed by a mixture of 1.25% p-formaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 20 min. Thereafter, a postfixation rinse in situ with the same buffer was performed for another 20 min.
Histochemistty.
The entire brain was removed, the operated side was marked, and the brainstem was cut through both facial nuclei in 50-Frnthick coronal sections on a Vibratome (FTB-vibracut; Plano, Marburg, Germany).
HRP activity was revealed using the incubation chamber of Paul1 and King (1983) simultaneously in sections from 12 brainstems (6 from placebo-treated rats and 6 from nimodipine-treated rats) according to the tetramethylbenzidine protocol of Mesulam (1978) .
Quantitative estimates
Counting of the labeled facial neurons was performed with the fractionator method (Gundersen, 1986) in every third 50 pm section through the facial nucleus both on the operated and on the untreated contralateral side of the brainstem as described previously (Neiss et al., 1992; Guntinas-Lichius et al., 1993 
RESULTS
All data presented here are the mean 5 SD of six rats per group unless stated otherwise.
Normal innervation of the whiskerpad Application of HRP solution into the whiskerpads of unoperated animals labeled 1280 5 113 (n = 12 facial nuclei of 6 rats) motoneurons, all of which were located exclusively in the lateral subdivision of the facial nucleus (Fig. 1) . This number and location are nearly equal to our results from a previous experiment, in which we counted 1278 t-97 (n = 42 facial nuclei of 42 rats) motoneurons projecting into the whiskerpad [Angelov et al. (1993) ; see page 216 and their Fig. 21 . The same data were obtained on the contralateral, i.e., the unoperated side of animals with unilateral FFA. Injection of HRP into the contralateral whiskerpad labeled 1286 ? 111 (n = 60) motoneurons in the placebo group and 1253 -t 103 (n = 60) motoneurons in the nimodipine group. There was no significant difference between these groups (unpaired t test), and the number of labeled neurons remained constant throughout the experiment (Table 1) ; i.e., the nimodipine treatment had no effect on the number of motoneurons on the unoperated side and did not obviously affect the retrograde transport of HRP.
When we amalgamated the data sets of placeboand nimodipine-treated animals, the normal facial lateral subnucleus of the Wistar rat contained 1269 2 108 (n = 120) motoneurons that projected into the whiskerpad.
Reinnervation
of the whiskerpad after FFA Placebo Injection of HRP into the whiskerpad on the side of operation did not label any neurons on the operated side of the brainstem at 10 DPO. The first HRP-marked motoneurons were detected 14 d after nerve suture (Table 1) .
The number of labeled neurons gradually increased and reached 1328 ? 154 at 42 DPO. Although this number was equal to the number of facial neurons that project into the whiskerpad under normal conditions (see Table 1 , Fig. 3 ), the labeled neurons were scattered throughout the facial nucleus, i.e., no somatotopic organization into subnuclei was evident (Fig. 2) . After 42 DPO, the number of HRP-labeled motoneurons on the operated side increased further, causing a hyperinnervation, also termed "polyneuronal innervation" (Rich and Lichtman, 1989; Son and Thompson, 1995a) . At 56 and 112 DPO, 12.7 and 32.6% more facial motoneurons were projecting into the mimetic muscles of the whiskerpad on the operated than on the unoperated contralatera1 side, respectively, of the same animals. When we pooled the data of 56 and 112 DPO and tested the neuron numbers on the operated versus unoperated side in the same animals with the t test for paired data, this hyperinnervation proved highly significant (p = 0.001).
Nimodipine
As in the placebo-treated animals, the first retrogradely labeled motoneurons in the facial nucleus appeared at 14 DPO (Table  1 ).
In the next 2 weeks, however, the increase in number of the HRP-marked neurons, i.e., the reinnervation of the mimetic musculature, proceeded much more rapidly than in placebo-treated animals (Table 1, Fig. 3 ). From 16 to 24 DPO, more facial neurons were labeled after FFA followed by nimodipine than after placebo treatment (Fig. 3) .
The acceleration of axonal sprouting by nimodipine occurred only during the first 3-4 postoperative weeks. At 42 DPO, the number of motoneurons that had reached the whiskerpad with nimodipine or placebo was the same as under normal conditions (Table 1, Fig. 3) . Thereafter, the number of HRP-labeled motoneurons increased further. At 56 and 112 DPO, 9.3 and 12.1% more facial neurons were labeled on the operated than on the unoperated side, respectively, in the same rats. Although modest, this hyperinnervation nevertheless proved significant (p = 0.001; t test for paired data).
Drug effect
With two-factorial ANOVA, both treatment time (factor A) and type of treatment (factor B) proved significant (p = 0.001 for A, B, and A+B). These results mean that the number of motoneurons that can be labeled by injection of HRP into the denervated target muscle depends on the time for regeneration, which is obvious, and on the postoperative drug treatment of the animals, which is the new result of our study. Figure 3 shows that 1000 ppm nimodipine administered as needed yielded two beneficial effects on facial reinnervation.
(1) In the early phase, nimodipine accelerated the axonal sprouting of facial motoneurons.
(2) In the final phase, nimodipine reduced the postoperative hyperinnervation.
The significance of these two effects was tested separately.
Early phase. Using the t test for unpaired data, the numbers of labeled neurons differ significantly between the respective placebo and nimodipine groups from 16 to 24 DPO (see Fig. 3 ). Because these are multiple tests, however, the p-values (Fig. 3, asterisks) have been corrected according to Bonferroni-Helm. With this correction, the mean data of the nimodipine-treated rats 16-24 DPO differ with p < 0.05 from those of the placebo-treated animals. The Bonferroni-Holm correction for multiple testing is a very conservative procedure, and in our data at 16 and 21 DPO, even the ranges of neuron numbers did not overlap between the six placebo-treated rats and six nimodipine-treated rats at each Final phase. At 56 and 112 DPO, the t test for paired data independently showed in both treatment groups a significant hyperinnervation (see above) that appeared more modest after nimodipine therapy (Fig. 3 , Table 1 ). When we used the t test for unpaired data, this difference between placebo-and nimodipinetreated rats was highly significant (p = 0.001). In conclusion, nimodipine cannot prevent fully, but does suppress greatly the pathological hyperinnervation (polyneuronal innervation) of the whiskerpad that follows transection and suture of the facial nerve.
DISCUSSION
Methodological approach In this study, neurons were counted after axotomy and subsequent retrograde labeling with HRP. Because we did not measure the post-transectional axonal growth directly-rather, we measured the uptake of a neuronal tracer injected into the target musculature--the possible critique regarding the extent to which our counts accurately reflect sprouting should be addressed carefully. Three sound arguments support the chosen approach as reasonable and appropriate.
First, a remote diffusion of the HRP solution from the whiskerpad to the proximal stump of the transected facial nerve can be ruled out completely: if such diffusion had occurred, labeling of facial motoneurons also would have resulted in experimental animals with the shorter postoperative survival period of 10 DPO. This, however, was never detected. Second, even the earliest axonal sprouts (or neuroma) that grow after axotomy are capable of incorporation and retrograde transport of HRP (Sparrow and Kiernan, 1979; Olsson, 1980) . Third, there is no uptake of HRP by lethally injured, i.e., nonregenerating motoneurons (Angelov et al., 1993) and, likewise, there is no neuronal labeling from muscles with electromyographic evidence of denervation (Anonsen et al., 1986) . Therefore, only those regenerated motoneurons can be labeled, the axons of which are projecting into the target muscle. rats-t test fir unpaired data: **p i 0.01, ***p < 0.001.
Nimodipine-accelerated sprouting of facial nerve fibers Our quantitative estimates show that 14-28 d after FFA, the number of facial axons (or axonal branches) that have reached the target successfully is higher in nimodipine-treated rats than in placebo-treated rats (Table 1, Fig. 3 ). In this way, the proposed favorable effect of nimodipine on neuronal recovery (Poplawsky, 1990; Nelson et al., 1993; Neiss et al., 1993) has been confirmed morphologically under conditions of a simple but reliable comparative experiment.
We are not aware of the mechanism of nimodipine stimulation of sprouting. The precise mechanism of action of this agent is still unknown (for review, see Wadworth and McTavish, 1992) . So far, our explanation concurs with the common hypothesis that a dual effect (on both perikarya and neurites) occurred. The neuroprotective effect for the perikarya has been suggested previously: as nimodipine passes the blood-brain barrier and binds to specific dihydropyridine receptors, it may prevents the influx of Ca'+ into the injured neuronal cell bodies (Schanne et al., 1979; Siesjo, 1981; Belleman et al., 1983; Simon et al., 1984; Kazda et al., 1985; Van den Kerckhoff and Drewes, 1985) . The second, peripheral beneficial effect of nimodipine on the axonal branches involves the fine regulation of intracellular calcium in outgrowing sprouts. It is well known that most of the voltage-sensitive Ca2+ channels are localized on the outgrowing axonal sprouts (Anglister et al., 1982) , the metabolism of which depends on a narrow range of intracellular Ca2+ concentrations (Meyer, 1989; Kater and Mills, 1991) . Via a specific binding to the dihydropyridine receptors, the L-type Ca'+ channel antagonist nimodipine reduces the influx of Ca2' into the injured neurons and, thus, may exert a beneficial growth promoting action.
Nimodipine suppression of post-transectional hyperinnervation In placebo-treated animals, the continuing sprouting of the facial axons after 42 DPO causes a massive (-30%) hyperinnervation. This term was introduced earlier (Angelov et al., 1993; Neiss et al., 1993) and means that paradoxically, after peripheral nerve lesion, the axonal branches of more motoneurons project to the target muscles than under normal conditions. The primary reason for this is the misguidance of the regenerating fibers to inappropriate peripheral targets (Thomander, 1984; Aldskogius and Thomander, 1986; Rich and Lichtman, 1989; Matsumoto, 1992; Angelov et al., 1993; Son and Thompson, 1995a,b) . Despite the use of presently available microsurgical techniques for repair of injured peripheral nerves (i.e., cleaning of the wound, gentle tissue handling, good adaptation and coaption, use of a minimal number of sutures, and absence of tension) (Millesi, 1979) , a substantial mismatching of motoneurons and muscles always occurs after transection and subsequent regeneration within a nerve trunk. After nerve transection in adult animals, virtually all neurons survive, but the regenerating axons appear to grow in a relatively random manner ("escaped fibers"), causing a considerable disarray of the facial nucleus. This loss of somatotopic organization in the facial nucleus and the subsequent hyperinnervation of targets are morphological correlates of the phenomenon of "misdirected resprouting"
(also termed excessive, multiple, redundant, or aberrant reinnervation, or misdirected regrowth of axons). Consequently, the coordinated activity of individual muscles is impaired (Monserrat and Benito, 1988; Wasserschaff, 1990 ) (for review, see Sumner, 1990 ) and abnormal associated movements (synkinesis), hemifacial spasms, or contractures may develop (Yagi and Nakatani, 1986) .
We cannot state whether the axonal branches of all HRPlabeled neurons terminate in the mimetic muscles as functioning motor endplates-the HRP method reveals and proves only the presence of axonal branches, but not the presence of motor endplates formed by them (Flumerfelt et al., 1986) . This question was not the subject of the present study and requires systematic investigation of reinnervated muscle fibers, which is presently under way.
Hyperinnervation also occurs in nimodipine-treated rats; however, it does not exceed 15%. At first sight, nimodipine appears to have a paradoxical effect after transection of a peripheral motor nerve: on one hand, it stimulates and accelerates axonal resprouting, and on the other, it suppresses the excessive neurotization (hyperinnervation, polyneuronal innervation) of the target. In our opinion, this restriction of further sprouting is attributable not to a suppressive effect of nimodipine, but to the very rapid and functionally better reinnervation of the whiskerpad muscles induced by it.
Under normal conditions (placebo treatment), the ruptured cell membranes of the proximal and distal portions of the transected axons are resealed 5-30 min after the transection (Yawo and Kuno, 1985) . Thereafter, the proximal stump gradually regrows, fostered by the neural cell surface molecule of the transmembrane glycoprotein Ll, nerve cell adhesion molecule (N-CAM), myelinassociated glycoprotein PO, and the extracellular matrix components laminin and tenascin (for review, see Martini, 1994) . The regenerating axons are guided by the Schwann cell processes (Son and Thompson, 1995a,b) , and their growth within the Schwann cell basal lamina tubes is synchronous with the withdrawal and degeneration of the axonal remnants of the distal stump (for review, see Fawcett and Keynes, 1990) . Before this, however, the distal nerve stump (together with its injured Schwann cells) and the denervated target secrete a palette of tropic and trophic factors, e.g., nerve growth factor (for review, see Seeburger and Springer, 1993) insulin-like growth factor (for review, see Lewis et al., 1993) basic fibroblast growth factor (Grothe and Unsicker, 1992) brain-derived neurotrophic factor (Hofer and Barde, 1988), and ciliary neurotrophic factor (Sendtner et al., 1990 (Sendtner et al., , 1992 ) which promote and/or enhance motor neuronal sprouting.
In our model, the growing axons and their branches reach the neuromuscular junction sites between 10 and 14 DPO. However, they still do not release neurotransmitters (Dennis and Miledi, 1974) . The first miniature end-plate potentials (MEPPs) appear -2 weeks after crush (McArdle and Albuquerque, 1973 ) and probably later after transection, because this is a more severe lesion of the nerve. Particularly in these early stages of reinnervation, the Ca*+-dependent release mechanisms are highly efficient, i.e., the influx of Ca2+ Increases the frequency of MEPPs. The reason for this is the low buffering capacity of the regenerating nerve terminals for free intracellular Ca"', which would allow a stronger stimulatory action of the Ca'+ that would enter the presynaptic ending (Kater et al., 1988) . Despite this rather high efficiency, however, the frequency of the MEPPs remains far below normal (Carmignoto et al., 1983) . In consequence, synchronously with the ongoing secretion of all neurotrophic factors (see above), these poorly innervated facial muscles accumulate N-CAMS, which enhance their attractiveness to axons (Covault and Sanes, 1985) . This may be the cause, in part, for the well documented hyperinnervation (Thomander, 1984; Aldskogius and Thomander, 1986; Angelov et al., 1993; Neiss et al., 1993) . By reducing the amount of calcium influx into the axoplasm of the resprouting nerve fiber, the treatment with nimodipine may provide the necessary optimum level ("set-point")
of Ca'+ influx that promotes accelerated growth cone elongation (Mattson and Kater, 1987; Kater et al., 1988; Kater and Mills, 1991; Fields et al., 1993) . However, it further reduces the buffering capacity of the terminals for Ca'+, which might render their responsiveness to Ca2+ even stronger. This would yield MEPPs with higher frequency. In this way, a much earlier and qualitatively better reinnervation of the facial muscles is achieved, which may lead to a partial reduction in the secretion of neurotrophic agents (see above) which, in turn, may reduce the postregeneration hyperinnervation.
In conclusion, we suggest that it is the acceleration of muscle innervation itself that suppresses the final stage hyperinnervation. Aldskogius H, Thomander L (1986) 
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